Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**NBT-NM108** is an investigational, orally administered botanical high-fiber nutritional formulation developed to remodel the gut microbiome. The formula promotes growth and metabolic activity of beneficial fiber-fermenting gut bacteria, described by Notitia as the Foundation Guild, with the intended effects of improving microbial diversity and function, increasing short-chain-fatty-acid production, and reducing dysbiosis-associated inflammation. It has been evaluated in phase 2 studies for COVID-19-related and gastrointestinal indications, multiple sclerosis, Prader-Willi syndrome-associated hyperphagia, and chemotherapy-associated diarrhea. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/botanical-based-agent-nbt-nm108))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NBT-NM108.